advertisement

Seminiar 30-11-2013 Longziekten en Osteoporosis

0 %
100 %
advertisement
Information about Seminiar 30-11-2013 Longziekten en Osteoporosis
Health & Medicine

Published on March 6, 2014

Author: stichtingiwo

Source: slideshare.net

Description

Longziekten en Osteoporosis
advertisement

r e . M . t u o W Osteoporosis and COPD E.F.M. Wouters Department of Respiratory Medicine Maastricht University

Disclosures t u o W •  Member Scientific Committee Eclipse (GSK) •  Lectures: Almirall, AstraZeneca, Chiesi, Danone, GSK, Novartis . M . r e •  Advisory board: AstraZeneca, Boehringer Ingelheim, GSK, Pfizer •  Research grants: AstraZeneca, Boehringer Ingelheim, Danone, GSK

Definition of COPD . M . r e t u o W Chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients Vestbo et al, Am J Respir Crit Care Med 2013

Background t u o W Muscle weakness Cardiovascular disease . M . COPD Depressive disorder r e Hypertension Osteoporosis Wouters EFM et al, Systemic effects in COPD. Chest 2002;121(5 Suppl):127S-30S. Barnes PJ et al, Systemic manifestations and comorbidities of COPD. ERJ 2009;33(5):1165-85.

30 24.9 Frequency (%) 25 20 15 10 5 0 . M . 17.8 7.0 2.3 0 1 2 r e t u o W Number of objectively identified comorbidities 19.2 17.8 8.0 2.3 3 4 5 6 7 0.5 8 No. of comorbidities per patient Vanfleteren et al, Am J Respir Crit Care Med 2013

Frequency (%) 60 48 50 40 30 . M . 20 10 0 5 9 14 16 21 r e t u o W Frequencies of objectively identified comorbidities 22 23 28 31 53 54 36 Vanfleteren et al, Am J Respir Crit Care Med 2013

Low  body   weight   Smoking   Age   Gender   Inac7vity     Systemic   inflamma7on     Systemic   Cor7costeroids     Vitamin  D   deficiency   Rib  cage   fractures   . M . Osteoporosis   r e t u o W Pathogenesis of osteoporosis in COPD Exacerba7ons    ↑   Risk  for   fractures  ↑   Morbidity  and   Mortality  ↑   Vertebral   fractures   Decline  of  FEV1   Lehouck et al, Chest 2011

r e . M . t u o W Prevalence of osteoporosis in COPD

r e t u o W Prevalence of osteoporosis in COPD 35   30   25   20   15   10   5   0   Osteoporosis:  Tscores  –2.5   . M . no   mild   male   female   moderate   severe   Sin et al, Am J Med 2003

Osteoporosis in COPD t u o W Odds  ra7o   Normal     Mild  obstruc7on   Moderate  obstruc7on Severe  obstruc7on         . M .         r e          Reference    1.3    2.1    2.4   Airflow  obstruc7on,  independent  of  age,  body  mass  index  and  medica7ons  including   recent  use  of  cor7costeroids,  increased  the  risk  of  osteoporosis  in  a  severity-­‐ dependent  fashion.   Sin et al, Am J Med 2003

osteoporosis osteopenia 100% 41 50 Percentage of subject group 80% 5 18 13 no bone loss 32 . M . 50 60% 40% r e t u o W Osteoporosis in COPD 47 50 55 32 20% 12 0% low BMI-low FFMI n=16 norm al BMI-low FFMI n=17 norm al BMInorm al FFMI n=44 Healthy subjects n=38 Bolton C et al, AJRCCM 2004

. M . r e t u o W Prevalence of osteoporosis in COPD Graat-Verboom et al, ERJ 2009

. M . r e t u o W Prevalence of osteoporosis in COPD Graat-Verboom et al, ERJ 2009

r e t u o W Prevalence of osteoporosis in COPD 18   16   14   12   10   8   6   4   2   0   . M . without  COPD   n=  14,828   P<0.001   with  COPD   n=  995   Schnell et al, BMC Pulmonary Medicine 2012

. M . r e t u o W Prevalence of osteoporosis in COPD Miller et al, Respir Med 2013

Comorbidity in COPD Stage II Heart trouble 26% Heart attack 10% Stroke 4% Heart failure Arrhythmia Osteoporosis Diabetes . M . 7% 12% 13% 11% Inflamm. Bowel Dis. 6% Peptic ulcer 11% r e t u o W Stage III Stage IV p-value 25% 25% 0.992 8% 8% 0.457 3% 3% 0.327 6% 9% 0.287 12% 10% 0.721 14% 12% 0.785 9% 11% 0.118 3% 6% 0.045 11% 8% 0.206 Reflux/heartburn 31% 23% 21% <0.001 Depression requring tx. 16% 17% 15% 0.516 Agusti A et al, Respir Res 2010

r e t u o W Prevalence of osteoporosis in COPD DXA-scan 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% . M . GOLD I GOLD II Normal BMD Osteopenia Osteoporosis GOLD III GOLD IV Graat et al, J Bone Miner Res 2011

r e t u o W Definitions of 13 comorbidities Underweight: BMI < 21 kg·m-2 (Celli et al., N Engl J Med 2004) Muscle wasting: FFMI < 16 kg·m-2 for men or < 15 kg·m-2 for women (Schols et al., Am J Clin Nutr 2005) Obesity: BMI ≥ 30 kg·m-2 (WHO) Renal failure: Osteoporosis: Anemia: . M . eGFR (Cockroft and Gault) < 60 ml·min-1 (KDOQI, Am J Kidney Dis 2007) T-score < -2,5 on the local sites hip and lumbal spine or whole body (Graat-Verboom et al., J. Osteoporos 2010) Hemoglobin level <13 g·dL-1 (8,1 mmol/L) in men and <12 g·dL-1 (7,5 mmol/L) in women (WHO) Vanfleteren et al, Am J Respir Crit Care Med 2013

Frequency (%) 60 48 50 40 30 . M . 20 10 0 5 9 14 16 21 r e t u o W Frequencies of objectively identified comorbidities 22 23 28 31 53 54 36 Vanfleteren et al, Am J Respir Crit Care Med 2013

Cardiovascular Metabolic . M . Less comorbidity r e t u o W Identification of five comorbidity clusters Cachectic Psychological Vanfleteren et al, Am J Respir Crit Care Med 2013

r e t u o W Characteristics of comorbidity clusters ‘less comorbidity’ ‘cardiovascular’ CLUSTER 2 CLUSTER 3 CLUSTER 4 CLUSTER 5 67 49 44 33 20 2.5 ± 1.4 3.8 ± 1.7 4.2 ± 1.4 4.4 ± 1.1 4.1 ± 1.8 Renal impairment 16 24 45 9 5 Anaemia, % 9 4 2 3 5 3 98 43 100 5 30 14 0 61 15 0 0 66 3 0 12 10 98 0 20 52 14 43 91 60 42 16 25 67 40 27 37 52 0 35 5 28 26 0 84 6 23 7 6 68 56 67 12 81 53 2 11 7 13 32 Clinical characteristics n No. of comorbidiites Hypertension, % Obesity, % Underweight, % Muscle wasting, % Hyperglycaemia, % Dyslipidaemia, % Osteoporosis, % Anxiety, % Depression, % Atherosclerosis, % CLUSTER 1 . M . Myocardial infarction, % ‘cachectic’ ‘metabolic’ ‘psychologic’ Vanfleteren et al, Am J Respir Crit Care Med 2013

Osteoporosis in COPD . M . t u o W r e

r e . M . t u o W

. M . r e t u o W Pulmonary emphysema and osteoporosis in COPD Ohara et al, Chest 2008

Corticosteroids: inhaled . M . r e t u o W Risk factors for osteoporosis in COPD Vit D deficiency Systemic inflammation Emphysema

. M . r e t u o W Pathophysiology of glucocorticoid-induced effects on bone cells Den Uyl et al, Curr Rheumatol Rep 2011

. M . r e t u o W Inhaled steroids and osteoporosis Ferguson et al, Chest 2009

. M . r e t u o W Inhaled steroids and osteoporosis: Change in hip BMD Ferguson et al, Chest 2009

. M . r e t u o W Inhaled steroids and osteoporosis: spine BMD Ferguson et al, Chest 2009

Bone fractures in COPD t u o W Rate  of  fracture  per  1,000  treatment  years   22   . M . 21   20   19   18   17   Placebo  Group   n=1,544   r e SAL  Group   n=1,542   FP  Group   n=1,552   SFC  Group   n=1,546   Ferguson et al, Chest 2009

Bone fractures in COPD t u o W Probability  of  fracture  by  3  yr,  %   7   6   . M . 5   4   3   2   1   0   Placebo  Group   n=1,544   r e SAL  Group   n=1,542   FP  Group   n=1,552   SFC  Group   n=1,546   Ferguson et al, Chest 2009

Corticosteroids: inhaled . M . r e t u o W Risk factors for osteoporosis in COPD Vit D deficiency Systemic inflammation Emphysema

r e . M . t u o W Vitamin D metabolism

. M . r e t u o W Vitamin D synthesis pathways

Vit D deficiency in COPD r e t u o W 25-­‐OHD  levels  >  30  ng/ml   25-­‐OHD  levels  20  -­‐  30  ng/ml   . M . 25-­‐OHD  levels  <  20  ng/ml   Janssens et al, Thorax 2010

Vit D status in COPD . M . r e t u o W Romme et al, Ann Med 2013

. M . 25-­‐OHD  levels  <  30  ng/ml:  69  %   25-­‐OHD  levels  <  20  ng/ml:  39  %   25-­‐OHD  levels  <  10  ng/ml:  8.7  %   r e t u o W Vit D and lung function in COPD r  =  0.116   p  <  0.01   Berg et al, Respir Med 2013

. M . r e t u o W Vit D and lung structure in COPD r  =  0.141   p  <  0.01   Berg et al, Respir Med 2013

Vit D and GOLD severity <   . M . >   r e t u o W Berg et al, Respir Med 2013

. M . r e t u o W Risk factors for osteoporosis in COPD Graat-Verboom, Bone 2012

r e t u o W Bone mineral density and Vit D BMI   Age     . M . 25  (OH)D     R2=0.22   Romme et al, Ann Med 2013

. M . r e t u o W Vitamin D beyond bones in COPD Janssens et al, AJRCCM 2009

Corticosteroids: inhaled . M . r e t u o W Risk factors for osteoporosis in COPD Vit D deficiency Systemic inflammation Emphysema

. M . r e t u o W Pathogenesis of osteoporosis in COPD Lehouck et al, Chest 2011

. M . r e t u o W OPG/RANK/RANKL system in COPD with osteoporosis Zhang et al, COPD 2013

. M . r e t u o W OPG/RANK/RANKL system in COPD with osteoporosis Zhang et al, COPD 2013

. M . r e t u o W OPG/RANK/RANKL pathway in COPD with osteoporosis Bai et al, Respir Research 2011

. M . r e t u o W OPG/RANK/RANKL pathway in COPD with osteoporosis Bai et al, Respir Research 2011

. M . r e t u o W OPG/RANK/RANKL pathway in COPD with osteoporosis Bai et al, Respir Research 2011

Inflammatory  markers   YES   N   283   CRP,  mg/L   2.6  +  5   Fibrogen,  mg/dL   462  +  135   IL-­‐6,  pg/mL   1.4  +  2   IL-­‐8,  pg/mL   5.4  +  8.3   TNF-­‐alpha,  pg/mL   2.4  +  4   SPD,  ng/mL   117  +  89   CCL-­‐18,  ng/mL   CC-­‐16,  ng/mL   r e t u o W Inflammation data and osteoporosis in COPD NO   P-­‐value   1730   3.3  +  6   0.035   446  +  126.5   0.310   1.5  +  2   0.371   7.3  +  10.2   0.272   2.4  +  10   0.994   119  +  87   0.971   108  +  57   105  +  53   0.954   4.8  +  3.6   5.0  +  3.5   0.947   . M . Miller J et al, Respir Med 2013

. M . r e t u o W Biomarkers  in  COPD   Agus7  et  al,  Plos  One  2012  

Conclusions t u o W 1.  Osteoporosis is highly prevalent in COPD 2.  The pathogenesis of bone abnormalities in COPD is multifactorial . M . r e 3.  Growing evidence of a link between emphysema and osteoporosis: The implosive COPD phenotype?

Add a comment

Related presentations

Related pages

Seminiar 30-11-2013 Longziekten en Osteoporosis ...

Over Stichting IWO. De Stichting Interdisciplinaire Werkgroep Osteoporose (IWO) wordt bestuurd door artsen die werkzaam zijn in verschillende organisaties ...
Read more

NORTON 30.11.2013 - Documents - docslide.us

Seminiar 30-11-2013 Longziekten en Osteoporosis ... Seminar 30-11-2013 Sarcopenie en osteoporose Presentatie Sarcopenie en osteoporose
Read more

(2012-02-16) osteoporosis en A.P. PPT - Documents

Share (2012-02-16) osteoporosis en A.P. PPT. ... Seminiar 30-11-2013 Longziekten en Osteoporosis. Osteoporosis. Osteoporosis. Login or Join. Processing
Read more

Osteoporose | LinkedIn

Seminar 30-11-2013 Sarcopenie en osteoporose . ... Seminar 09-04-2014 Osteoporose en cni . 363 Views. stichtingiwo. Seminar 09-04-2014 Osteoporose bij COPD.
Read more

Ostéoporose | LinkedIn

Seminar 30-11-2013 Sarcopenie en osteoporose . ... Seminar 09-04-2014 Osteoporose en cni . 363 Views. stichtingiwo. Seminar 09-04-2014 Osteoporose bij COPD.
Read more

Stichting Interdisciplinaire Werkgroep Osteoporose - HubSlide

Author: Stichting Interdisciplinaire Werkgroep Osteoporose. ... Seminar 26-11-10 - Richtlijn osteoporose en fractuurpreventie, derde herziening (2010)
Read more

Main Document 30-11-2013 - Documents

Main Document 30-11-2013. by lennie-adams. on Jul 20, 2015. Report Category: Documents. Download: 0 Comment: 0. 60. views. Comments. Description.
Read more

Workshop hes ll14 - slidesearch.org

1. 22-12-2014 1 kaak Bisfosfonaat geen weldaad voor de BISFOSFONAAT GERELATEERDE OSTEONECROSE van de kaak (Bronj /ONJ) j.hes,nov 2014 j ...
Read more